Savara (Savara) Retained Earnings : $-413.72 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Savara Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Savara's retained earnings for the quarter that ended in Mar. 2024 was $-413.72 Mil.

Savara's quarterly retained earnings declined from Sep. 2023 ($-377.27 Mil) to Dec. 2023 ($-393.37 Mil) and declined from Dec. 2023 ($-393.37 Mil) to Mar. 2024 ($-413.72 Mil).

Savara's annual retained earnings declined from Dec. 2021 ($-300.52 Mil) to Dec. 2022 ($-338.67 Mil) and declined from Dec. 2022 ($-338.67 Mil) to Dec. 2023 ($-393.37 Mil).

Savara Retained Earnings Historical Data

The historical data trend for Savara's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Retained Earnings Chart

Savara Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-207.89

-257.51

-300.52

-338.67

-393.37

Savara Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-349.23	-360.67	-377.27	-393.37	-413.72

Savara Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Savara (NAS:SVRA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Savara (Savara) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

YB4P:Germany YB4P:Germany

Address

6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746

Website

https://www.savarapharma.com

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Executives

Matthew Pauls	director	9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance	officer: Chief Financial Officer	422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam	director	C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers	10 percent owner	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt	officer: Chief Medical Officer	208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay	director	HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121